본문 바로가기

US · 21 CFR

21 CFR Part 4

Regulation of Combination Products

eCFR, up to date as of 2026-11-12

조항 목차

  1. 4.1What is the scope of this subpart?
  2. 4.2How does FDA define key terms and phrases in this subpart?
  3. 4.3What current good manufacturing practice requirements apply to my combination product?
  4. 4.4How can I comply with these current good manufacturing practice requirements for a co-packaged or single-entity combination product?
  5. 4.100What is the scope of this subpart?
  6. 4.101How does the FDA define key terms and phrases in this subpart?
  7. 4.102What reports must you submit to FDA for your combination product or constituent part?
  8. 4.103What information must you share with other constituent part applicants for the combination product?
  9. 4.104How and where must you submit postmarketing safety reports for your combination product or constituent part?
  10. 4.105What are the postmarketing safety reporting recordkeeping requirements for your combination product or constituent part?
표지·목차 원문

Authority:21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360b-360f, 360h-360j, 360l, 360hh-360ss, 360aaa-360bbb, 360ddd, 360ddd-1, 371(a), 372-374, 379e, 381, 383, 394; 42 U.S.C. 216, 262, 263a, 264, 271.

Source:78 FR 4321, Jan. 22, 2013, unless otherwise noted.

출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16

Weekly Newsletter

FDA·EU·식약처 실사 지적, 매주 받아 보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

확인 메일의 버튼을 누르면 구독이 완료됩니다 · 언제든 해지할 수 있습니다